Find Hyaluronidase manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Finished Drug Prices

NA

26 RELATED EXCIPIENT COMPANIES

46EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 88755-39-9, Chembl2000337, Runx1/eto tetramerization-in-1, Nsc162496, Schembl16211954, Dtxsid40864143
Molecular Formula
C18H14O7
Molecular Weight
342.3  g/mol
InChI Key
PPEBBOHQEAQKSW-UHFFFAOYSA-N

Hyaluronidase
1 2D Structure

Hyaluronidase

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2,4-bis(1,3-benzodioxol-5-yl)-4-oxobutanoic acid
2.1.2 InChI
InChI=1S/C18H14O7/c19-13(11-2-4-15-17(6-11)25-9-23-15)7-12(18(20)21)10-1-3-14-16(5-10)24-8-22-14/h1-6,12H,7-9H2,(H,20,21)
2.1.3 InChI Key
PPEBBOHQEAQKSW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1OC2=C(O1)C=C(C=C2)C(CC(=O)C3=CC4=C(C=C3)OCO4)C(=O)O
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 88755-39-9

2. Chembl2000337

3. Runx1/eto Tetramerization-in-1

4. Nsc162496

5. Schembl16211954

6. Dtxsid40864143

7. Bdbm50392853

8. 2,3]dioxol-5-yl)-4-oxobutanoic Acid

9. Nsc-162496

10. Hy-151411

11. Cs-0611487

12. Ft-0627100

13. A937131

14. Butanoic Acid,4-bis[1,3-benzodioxol-5-yl]-4-oxo-

15. 2,4-bis(2h-1,3-benzodioxol-5-yl)-4-oxobutanoic Acid

2.3 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 342.3 g/mol
Molecular Formula C18H14O7
XLogP32.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass342.07395278 g/mol
Monoisotopic Mass342.07395278 g/mol
Topological Polar Surface Area91.3 Ų
Heavy Atom Count25
Formal Charge0
Complexity522
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

SIGMA TAU

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

SIGMA TAU

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

Reliable Biopharmaceutical Corpora...

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Reliable Biopharmaceutical Corpora...

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Fujifilm Diosynth Biotechnologies

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Fujifilm Diosynth Biotechnologies

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

SERAVAC BIOTECH PTY LTD

South Africa

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

SERAVAC BIOTECH PTY LTD

South Africa

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

SAFC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

SAFC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS Inactive-api JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Worthington Biochemical Corporatio...

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Worthington Biochemical Corporatio...

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Sichuan Deebio Pharmaceutical Co.,...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

08

BBI Solutions

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

BBI Solutions

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Avid Bioservices

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Avid Bioservices

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

10

Catalent Pharma Solutions

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Catalent Pharma Solutions

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Diosynth Bv

United Kingdom

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

01

Diosynth Bv

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 4489

Submission : 1982-02-02

Status : Inactive

Type : II

blank

02

BIO Partnering at JPM
Not Confirmed

02

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 16273

Submission : 2002-11-25

Status : Inactive

Type : II

blank

03

BIO Partnering at JPM
Not Confirmed

03

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 26086

Submission : 2012-05-24

Status : Inactive

Type : II

blank

04

Seravac Biotech Pty Ltd

South Africa

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

04

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 16622

Submission : 2003-05-30

Status : Inactive

Type : II

blank

05

Sigma F And D Div Ltd

U.S.A

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

05

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 3405

Submission : 1979-01-09

Status : Inactive

Type : II

blank

06

BIO Partnering at JPM
Not Confirmed

06

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 90

Submission : 1954-03-04

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-more

01

Biotech Showcase
Not Confirmed
arrow

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Certificate Number : R1-CEP 2001-068 - Rev 00

Status : Suspended by EDQM GMP non-compliance

Issue Date : 2007-04-04

Type : TSE

Substance Number : 912

blank

03

Biotech Showcase
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Borhyaluronidase alpha (genetical recombination)

Registration Number : 304MF10126

Registrant's Address : 14191 Myford Road Tustin, CA 92780, USA

Initial Date of Registration : 2022-08-24

Latest Date of Registration : 2022-08-24

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Borhyaluronidase alpha (genetical recombination)

Registration Number : 302MF10030

Registrant's Address : 1300 South Patterson Drive, Bloomington, Indiana 47403 USA

Initial Date of Registration : 2020-02-20

Latest Date of Registration : 2021-09-02

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

BMI Korea

South Korea
BIO Partnering at JPM
Not Confirmed
arrow

BMI Korea

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase

Registrant Name : Korea BMI Co., Ltd.

Registration Date : 2023-12-27

Registration Number : 20231227-210-J-1591

Manufacturer Name : Korea BMI Co., Ltd.

Manufacturer Address : 11, Cheomdan-ro 7-gil, Jeju-si, Jeju Special Self-Governing Province, Factory 2

blank

02

Humedix

South Korea
BIO Partnering at JPM
Not Confirmed
arrow

Humedix

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase

Registrant Name : Humedics Co., Ltd.

Registration Date : 2024-03-13

Registration Number : 20240313-210-J-1620

Manufacturer Name : Humedics Co., Ltd.

Manufacturer Address : 17 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do

blank

03

Humedix

South Korea
BIO Partnering at JPM
Not Confirmed
arrow

Humedix

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase

Registrant Name : Humedics Co., Ltd.

Registration Date : 2024-03-13

Registration Number : 20240313-210-J-1619

Manufacturer Name : Humedics Co., Ltd.

Manufacturer Address : 17 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do

blank

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase

Registrant Name : Korea Chorus Co., Ltd.

Registration Date : 2023-07-04

Registration Number : 20230704-210-J-1516

Manufacturer Name : Ningbo Linzyme Biosciences C...

Manufacturer Address : 8, Xingshun Road, Binhai New City, Xiaocao'e Town, Yuyao@11, Geodudanji 1-gil, Dongna...

blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase

Registrant Name : Insung Trading Co., Ltd.

Registration Date : 2021-12-07

Registration Number : 20211207-210-J-1171

Manufacturer Name : Ningbo Linzyme Biosciences C...

Manufacturer Address : 8, Xingshun Road, Binhai New city, Xiaocaoe town, Yuyao

blank

06

BIO Partnering at JPM
Not Confirmed
arrow

arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase

Registrant Name : Korea BMI Co., Ltd.

Registration Date : 2024-09-02

Registration Number : 20240902-210-J-1684

Manufacturer Name : Korea BMI Co., Ltd.

Manufacturer Address : 11, Cheomdan-ro 7-gil, Jeju-si, Jeju Special Self-Governing Province

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

HYALURONIDASE

NDC Package Code : 52221-201

Start Marketing Date : 2015-06-17

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

Hyaluronidase

About the Company : Bioindustria Laboratorio Italiano Medicinali L.I.M. S.p.A. has a long tradition in the pharmaceutical business and specializes in: large and small volume injectables with termin...

Bioindustria Laboratorio Italiano Medicinali L.I.M. S.p.A. has a long tradition in the pharmaceutical business and specializes in: large and small volume injectables with terminal sterilization or with aseptic process, lyophilised dosage forms, syrups, drops, tablets, capsules.
blank

02

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

Hyaluronidase

About the Company : The company is a professional manufacturer of active biological extracts. We adhere to the market-oriented business philosophy. The international and domestic markets take advantag...

The company is a professional manufacturer of active biological extracts. We adhere to the market-oriented business philosophy. The international and domestic markets take advantage of China's abundant raw material resources to develop animal organ extracts. The company mainly produces trypsin and trypsin. , chymotrypsin, trypsin enzymes , pancreatic kallikrein, pepsin, elastase, sodium, cytochrome C, hemoglobin, bovine liver extract, chondroitin sulfate, and other products, marketing the United States, Germany, Japan, Korea, etc. Countries and regions have established good long-term partnerships with customers around the world.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.


Lead Product(s): Efgartigimod Alfa,Hyaluronidase

Therapeutic Area: Neurology Brand Name: Vyvgart Hytrulo

Study Phase: Phase IIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 20, 2024

blank

01

Argenx

Netherlands
arrow
BIO Partnering at JPM
Not Confirmed

Argenx

Netherlands
arrow
BIO Partnering at JPM
Not Confirmed

Lead Product(s) : Efgartigimod Alfa,Hyaluronidase

Therapeutic Area : Neurology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.

Brand Name : Vyvgart Hytrulo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 20, 2024

blank

Details:

Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment and recombinant human hyaluronidase PH20, it is indicated for CIPD.


Lead Product(s): Efgartigimod Alfa,Hyaluronidase

Therapeutic Area: Neurology Brand Name: Vyvgart Hytrulo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Zai Lab

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 11, 2024

blank

02

Argenx

Netherlands
arrow
BIO Partnering at JPM
Not Confirmed

Argenx

Netherlands
arrow
BIO Partnering at JPM
Not Confirmed

Details : Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment and recombinant human hyaluronidase PH20, it is indicated for CIPD.

Brand Name : Vyvgart Hytrulo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 11, 2024

blank

Details:

Darzalex Faspro (daratumumab and hyaluronidase-fihj) in is being investgated as monotherapy for the treatment of adult patients with high-risk smouldering multiple myeloma.


Lead Product(s): Daratumumab,Hyaluronidase

Therapeutic Area: Oncology Brand Name: Darzalex Faspro

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 08, 2024

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Darzalex Faspro (daratumumab and hyaluronidase-fihj) in is being investgated as monotherapy for the treatment of adult patients with high-risk smouldering multiple myeloma.

Brand Name : Darzalex Faspro

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 08, 2024

blank

Details:

Argenx gains access to Halozyme's ENHANZE, a proprietary rHuPH20 enzyme for subcutaneous drug delivery, for six targets, including FcRn target, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).


Lead Product(s): Efgartigimod Alfa,Hyaluronidase

Therapeutic Area: Immunology Brand Name: Vyvgart Hytrulo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Argenx

Deal Size: $370.0 million Upfront Cash: $30.0 million

Deal Type: Collaboration October 03, 2024

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Argenx gains access to Halozyme's ENHANZE, a proprietary rHuPH20 enzyme for subcutaneous drug delivery, for six targets, including FcRn target, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).

Brand Name : Vyvgart Hytrulo

Molecule Type : Large molecule

Upfront Cash : $30.0 million

October 03, 2024

blank

Details:

Talvey (talquetamab, CD3 targeting) with Darzalex Faspro (daratumumab and hyaluronidase, CD38 targeting) antibodies are being investigated in patients with relapsed or refractory multiple myeloma.


Lead Product(s): Talquetamab,Daratumumab,Hyaluronidase

Therapeutic Area: Oncology Brand Name: Talvey

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2024

blank

05

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Talvey (talquetamab, CD3 targeting) with Darzalex Faspro (daratumumab and hyaluronidase, CD38 targeting) antibodies are being investigated in patients with relapsed or refractory multiple myeloma.

Brand Name : Talvey

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 27, 2024

blank

Details:

Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.


Lead Product(s): Ocrelizumab,Hyaluronidase

Therapeutic Area: Neurology Brand Name: Ocrevus Zunovo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 13, 2024

blank

06

F. Hoffmann-La Roche

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

F. Hoffmann-La Roche

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.

Brand Name : Ocrevus Zunovo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 13, 2024

blank

Details:

Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone is approved in the U.S. for patients with newly diagnosed multiple myeloma.


Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib

Therapeutic Area: Oncology Brand Name: Darzalex Faspro

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2024

blank

07

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone is approved in the U.S. for patients with newly diagnosed multiple myeloma.

Brand Name : Darzalex Faspro

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 30, 2024

blank

Details:

Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.


Lead Product(s): Efgartigimod Alfa,Hyaluronidase

Therapeutic Area: Neurology Brand Name: Vyvgart Hytrulo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2024

blank

08

Argenx

Netherlands
arrow
BIO Partnering at JPM
Not Confirmed

Argenx

Netherlands
arrow
BIO Partnering at JPM
Not Confirmed

Lead Product(s) : Efgartigimod Alfa,Hyaluronidase

Therapeutic Area : Neurology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Vyvgart Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, It is being developed for CIDP.

Brand Name : Vyvgart Hytrulo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

June 21, 2024

blank

Details:

Darzalex Faspro (daratumumab and hyaluronidase-fihj) with bortezomib, lenalidomide, and dexamethasone is evaluated in phase 3 trials for maintenance in newly diagnosed myeloma.


Lead Product(s): Daratumumab,Hyaluronidase,Lenalidomide

Therapeutic Area: Oncology Brand Name: Darzalex Faspro

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2024

blank

09

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Darzalex Faspro (daratumumab and hyaluronidase-fihj) with bortezomib, lenalidomide, and dexamethasone is evaluated in phase 3 trials for maintenance in newly diagnosed myeloma.

Brand Name : Darzalex Faspro

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 30, 2024

blank

Details:

Hyqvia is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It is approved as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy.


Lead Product(s): Immune Globulin,Hyaluronidase

Therapeutic Area: Neurology Brand Name: HyQvia

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2024

blank

10

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Lead Product(s) : Immune Globulin,Hyaluronidase

Therapeutic Area : Neurology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Hyqvia is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It is approved as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy.

Brand Name : HyQvia

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 29, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

AKORN INC

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

AKORN INC

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

HYALURONIDASE

Brand Name : HYDASE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 150 UNITS/ML

Approval Date :

Application Number : 21716

RX/OTC/DISCN :

RLD :

TE Code :

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

HYALURONIDASE

Brand Name : AMPHADASE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 150 UNITS/ML

Approval Date :

Application Number : 21665

RX/OTC/DISCN :

RLD :

TE Code :

blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

HYALURONIDASE

Brand Name : VITRASE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 6,200 UNITS/VIAL

Approval Date :

Application Number : 21640

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

HYALURONIDASE

Brand Name : VITRASE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 200 UNITS/VIAL

Approval Date :

Application Number : 21640

RX/OTC/DISCN :

RLD :

TE Code :

blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

HYALURONIDASE RECOMBINANT HUMAN

Brand Name : HYLENEX RECOMBINANT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 150 UNITS/ML

Approval Date :

Application Number : 21859

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

read-more
read-more

01

Xixia Pharmaceuticals (Pty) Ltd

Country
BIO Partnering at JPM
Not Confirmed
arrow

Xixia Pharmaceuticals (Pty) Ltd

Country
arrow
BIO Partnering at JPM
Not Confirmed

Hyaluronidase 1,500 i.u.

Brand Name : Hyalase

Dosage Form : INJ

Dosage Strength : 1500u.i.

Packaging : 1X10u.i.

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Taste Masking

read-more
read-more

API Stability Enhancers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Direct Compression

read-more
read-more

Co-Processed Excipients

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Hyaluronidase Manufacturers

A Hyaluronidase manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hyaluronidase, including repackagers and relabelers. The FDA regulates Hyaluronidase manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hyaluronidase API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Hyaluronidase manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Hyaluronidase Suppliers

A Hyaluronidase supplier is an individual or a company that provides Hyaluronidase active pharmaceutical ingredient (API) or Hyaluronidase finished formulations upon request. The Hyaluronidase suppliers may include Hyaluronidase API manufacturers, exporters, distributors and traders.

click here to find a list of Hyaluronidase suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Hyaluronidase USDMF

A Hyaluronidase DMF (Drug Master File) is a document detailing the whole manufacturing process of Hyaluronidase active pharmaceutical ingredient (API) in detail. Different forms of Hyaluronidase DMFs exist exist since differing nations have different regulations, such as Hyaluronidase USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Hyaluronidase DMF submitted to regulatory agencies in the US is known as a USDMF. Hyaluronidase USDMF includes data on Hyaluronidase's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hyaluronidase USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Hyaluronidase suppliers with USDMF on PharmaCompass.

Hyaluronidase JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Hyaluronidase Drug Master File in Japan (Hyaluronidase JDMF) empowers Hyaluronidase API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Hyaluronidase JDMF during the approval evaluation for pharmaceutical products. At the time of Hyaluronidase JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Hyaluronidase suppliers with JDMF on PharmaCompass.

Hyaluronidase KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Hyaluronidase Drug Master File in Korea (Hyaluronidase KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Hyaluronidase. The MFDS reviews the Hyaluronidase KDMF as part of the drug registration process and uses the information provided in the Hyaluronidase KDMF to evaluate the safety and efficacy of the drug.

After submitting a Hyaluronidase KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Hyaluronidase API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Hyaluronidase suppliers with KDMF on PharmaCompass.

Hyaluronidase CEP

A Hyaluronidase CEP of the European Pharmacopoeia monograph is often referred to as a Hyaluronidase Certificate of Suitability (COS). The purpose of a Hyaluronidase CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hyaluronidase EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hyaluronidase to their clients by showing that a Hyaluronidase CEP has been issued for it. The manufacturer submits a Hyaluronidase CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hyaluronidase CEP holder for the record. Additionally, the data presented in the Hyaluronidase CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hyaluronidase DMF.

A Hyaluronidase CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hyaluronidase CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Hyaluronidase suppliers with CEP (COS) on PharmaCompass.

Hyaluronidase NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hyaluronidase as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Hyaluronidase API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Hyaluronidase as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Hyaluronidase and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hyaluronidase NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Hyaluronidase suppliers with NDC on PharmaCompass.

Hyaluronidase GMP

Hyaluronidase Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Hyaluronidase GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hyaluronidase GMP manufacturer or Hyaluronidase GMP API supplier for your needs.

Hyaluronidase CoA

A Hyaluronidase CoA (Certificate of Analysis) is a formal document that attests to Hyaluronidase's compliance with Hyaluronidase specifications and serves as a tool for batch-level quality control.

Hyaluronidase CoA mostly includes findings from lab analyses of a specific batch. For each Hyaluronidase CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Hyaluronidase may be tested according to a variety of international standards, such as European Pharmacopoeia (Hyaluronidase EP), Hyaluronidase JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hyaluronidase USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty